
    
      Participants randomized to the treatment arm will receive ALXN2050 in a multiple-ascending
      doses fashion over 3 periods (treatment sequence ABC). Participants randomized to the control
      arms will be further randomized to 1 of 2 treatment sequences (treatment sequence DEF or GHI)
      to receive placebo or active control over 3 periods.
    
  